On January 10, 2020, Aligos Therapeutics closed the transaction. The company has received $125 million in an equity round of funding co-led by new investors Wellington Management Group LLP and a global investment management firm. The transaction included participation from 36 investors including new investors Janus Henderson Group plc (NYSE:JHG), Boxer Capital LLC, Cormorant Asset Management, LLC, Pivotal BioVenture Partners LLC and Logos Capital Management, LLC and returning investors Vivo Capital, LLC, Versant Venture Management, LLC, Novo Holdings A/S, Roche Venture Fund and an undisclosed healthcare fund.

The company received $85,000,001 pursuant to Regulation D.